A position paper discusses evolving corticosteroid strategies for sarcoidosis, noting a shift in therapeutic paradigms for steroid use. The text highlights interest in targeted molecular approaches, particularly mTOR pathway inhibitors, which have seen some success in sarcoidosis treatment.
It also emphasizes the need to elucidate the precise mechanisms by which steroids exert effects in sarcoidosis, despite decades of pragmatic use spanning over 70 years. Uncertainty is acknowledged regarding the exact steroid action and the broader applicability of mTOR-targeted therapies.
No new clinical outcomes or practice recommendations are provided in the source.
The Lancet Respiratory Medicine published a clinical update in Critical Care on 22 Jan 2026.
The item focuses on Considering molecular pharmacology for sarcoidosis treatment.
Review the original article for the full source wording and details.